Patents by Inventor Ole Hvilsted Olsen

Ole Hvilsted Olsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200010820
    Abstract: The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as polynucleotide constructs encoding such variants, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.
    Type: Application
    Filed: September 20, 2019
    Publication date: January 9, 2020
    Inventors: Henrik Oestergaard, Ole Hvilsted Olsen, Katrine Skaarup Larsen, Henning Stennicke
  • Publication number: 20180327479
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to modied Factor VIII molecules having decreased cellular uptake.
    Type: Application
    Filed: July 6, 2018
    Publication date: November 15, 2018
    Inventors: Henriet Meems, Alexander Benjamin Meijer, Koenraad Mertens, Ole Hvilsted Olsen, Kasper Lamberth, Peder Lisby Noerby, Laust Bruun Johnsen, Marianne Hjortnes Kjalke, Henning Ralf Stennicke, Johannes Jacobus Voorberg, Maartje Van Den Biggelaar
  • Patent number: 10047142
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to modied Factor VIII molecules having decreased cellular uptake.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: August 14, 2018
    Assignees: Novo Nordisk A/S, Sanquin Blood Supply Foundation
    Inventors: Henriet Meems, Alexander Benjamin Meijer, Koenraad Mertens, Ole Hvilsted Olsen, Kasper Lamberth, Peder Lisby Noerby, Laust Bruun Johnsen, Marianne Hjortnes Kjalke, Henning Ralf Stennicke, Johannes Jacobus Voorberg, Maartje Van Den Biggelaar
  • Publication number: 20180179262
    Abstract: The present invention relates to VWF compounds as well as compositions suitable for treatment of blood clotting diseases.
    Type: Application
    Filed: February 8, 2018
    Publication date: June 28, 2018
    Inventors: Gert Bolt, Ditte Maria Karpf, Frederik Rode, Jesper Haaning, Kirstine Roepstorff, Lars Thim, Maj Petersen, Marianne Hjortnaes Kjalke, Ole Hvilsted Olsen, Jens Jacob Hansen
  • Publication number: 20180142227
    Abstract: The present invention relates to modified coagulation Factor VII polypeptides exhibiting increased resistance to antithrombin inactivation and enhanced proteolytic activity. The present invention also relates to polynucleotide constructs encoding such polypeptides, vectors and host cells comprising and expressing such polynucleotides, pharmaceutical compositions, uses and methods of treatment.
    Type: Application
    Filed: January 17, 2018
    Publication date: May 24, 2018
    Applicant: Novo Nordisk HealthCare AG
    Inventors: Henrik Oestergaard, Prafull S. Gandhi, Ole Hvilsted Olsen
  • Publication number: 20170198274
    Abstract: The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as polynucleotide constructs encoding such variants, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.
    Type: Application
    Filed: February 24, 2017
    Publication date: July 13, 2017
    Inventors: Henrik Oestergaard, Ole Hvilsted Olsen, Katrine Skaarup Larsen, Henning Stennicke
  • Publication number: 20170114147
    Abstract: The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy.
    Type: Application
    Filed: January 6, 2017
    Publication date: April 27, 2017
    Inventors: Ida Hilden, Berit Olsen Krogh, Jes Thorn Clausen, Ole Hvilsted Olsen, Jens Breinholt, Brian Lauritzen, Brit Binow Soerensen
  • Publication number: 20170096655
    Abstract: The present invention relates to modified coagulation Factor VII polypeptides exhibiting increased resistance to antithrombin inactivation and enhanced proteolytic activity. The present invention also relates to polynucleotide constructs encoding such polypeptides, vectors and host cells comprising and expressing such polynucleotides, pharmaceutical compositions, uses and methods of treatment.
    Type: Application
    Filed: May 18, 2016
    Publication date: April 6, 2017
    Inventors: Henrik Oestergaard, Prafull S. Gandhi, Ole Hvilsted Olsen
  • Publication number: 20170066813
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to modied Factor VIII molecules having decreased cellular uptake.
    Type: Application
    Filed: November 18, 2016
    Publication date: March 9, 2017
    Inventors: Henriet Meems, Alexander Benjamin Meijer, Koenraad Mertens, Ole Hvilsted Olsen, Kasper Lamberth, Peder Lisby Noerby, Laust Bruun Johnsen, Marianne Hjortnes Kjalke, Henning Ralf Stennicke, Johannes Jacobus Voorberg, Maartje Van Den Biggelaar
  • Patent number: 9574011
    Abstract: The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: February 21, 2017
    Assignee: Novo Nordisk A/S
    Inventors: Ida Hilden, Berit Olsen Krogh, Jes Thorn Clausen, Ole Hvilsted Olsen, Jens Breinholt, Brian Lauritzen, Brit Binow Soerensen
  • Publication number: 20170015729
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to conjugated Factor VIII molecules fused to a polypeptide such as e.g. an antibody binding protein or a Fc domain.
    Type: Application
    Filed: October 4, 2016
    Publication date: January 19, 2017
    Applicant: Novo Nordisk A/S
    Inventors: Gert Bolt, Kristian Kjaergaard, Peder Lisby Noerby, Ole Hvilsted Olsen
  • Patent number: 9493543
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to conjugated Factor VIII molecules fused to a polypeptide such as e.g. an antibody binding protein or a Fc domain.
    Type: Grant
    Filed: February 10, 2011
    Date of Patent: November 15, 2016
    Assignee: Novo Nordisk A/S
    Inventors: Gert Bolt, Kristian Kjaergaard, Peder Lisby Noerby, Ole Hvilsted Olsen
  • Publication number: 20160318991
    Abstract: The present invention relates to VWF compounds as well as compositions suitable for treatment of blood clotting diseases.
    Type: Application
    Filed: May 4, 2016
    Publication date: November 3, 2016
    Inventors: Gert Bolt, Ditte Maria Karpf, Frederik Rode, Jesper Haaning, Kirstine Roepstorff, Lars Thim, Maj Petersen, Marianne Kjalke, Ole Hvilsted Olsen, Jens Jacob Hansen
  • Publication number: 20160264645
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to stabilized Factor VIII molecules conjugated with a half life extending moiety as well as use of such molecules.
    Type: Application
    Filed: June 1, 2016
    Publication date: September 15, 2016
    Inventors: Henrik Oestergaard, Marianne Kjalke, Ole Hvilsted Olsen, Lars Thim, Henning Ralf Stennicke
  • Publication number: 20160207977
    Abstract: The present invention relates to Von Willebrand (VWF) compounds as well as compositions suitable for treatment of blood clotting diseases. The present invention also relates to pharmaceutical compositions, freeze-dried or liquid, comprising (i) a Factor VIII molecule and (ii) a VWF compound.
    Type: Application
    Filed: June 10, 2014
    Publication date: July 21, 2016
    Inventors: Ole Hvilsted Olsen, Marianne Hjortnaes Kjalke, Maj Petersen, Lars Thim, Kirstine Roepstorff, Jens Jacob Hansen, Jesper Haaning, Frederik Rode, Ditte Maria Karpf, Christian Rischel, Gert Bolt
  • Patent number: 9370583
    Abstract: The present invention relates to modified coagulation Factor VII polypeptides exhibiting increased resistance to antithrombin inactivation and enhanced proteolytic activity. The present invention also relates to polynucleotide constructs encoding such polypeptides, vectors and host cells comprising and expressing such polynucleotides, pharmaceutical compositions, uses and methods of treatment.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: June 21, 2016
    Assignee: NOVO NORDISK HEALTHCARE AG
    Inventors: Henrik Oestergaard, Prafull S. Gandhi, Ole Hvilsted Olsen, Carsten Behrens, Paul L. DeAngelis, Friedrich Michael Haller
  • Patent number: 9371370
    Abstract: The present invention relates to modified coagulation Factor VII polypeptides exhibiting increased resistance to antithrombin inactivation and enhanced proteolytic activity. The present invention also relates to polynucleotide constructs encoding such polypeptides, vectors and host cells comprising and expressing such polynucleotides, pharmaceutical compositions, uses and methods of treatment.
    Type: Grant
    Filed: October 15, 2014
    Date of Patent: June 21, 2016
    Assignee: NOVO NORDISK HEALTHCARE AG
    Inventors: Henrik Oestergaard, Prafull S. Gandhi, Ole Hvilsted Olsen
  • Publication number: 20160120954
    Abstract: The present invention relates to pharmaceutical compositions suitable for treatment of haemophilia.
    Type: Application
    Filed: November 6, 2015
    Publication date: May 5, 2016
    Inventors: Gert Bolt, Ditte M. Karpf, Frederik Rode, Jesper Haaning, Kirstine Roepstorff, Lars Thim, Maj Petersen, Marianne Kjalke, Ole Hvilsted Olsen, Peder L. Noerby, Jens J. Hansen
  • Publication number: 20160120992
    Abstract: The present invention relates to modified coagulation Factor VII polypeptides exhibiting increased resistance to antithrombin inactivation and enhanced proteolytic activity. The present invention also relates to polynucleotide constructs encoding such polypeptides, vectors and host cells comprising and expressing such polynucleotides, pharmaceutical compositions, uses and methods of treatment.
    Type: Application
    Filed: November 9, 2015
    Publication date: May 5, 2016
    Inventors: Henrik Oestergaard, Prafull S. Gandhi, Ole Hvilsted Olsen, Carsten Behrens, Paul L. DeAngelis, Friedrich Michael Haller
  • Patent number: 9321827
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to modied Factor VIII molecules having decreased cellular uptake.
    Type: Grant
    Filed: September 14, 2011
    Date of Patent: April 26, 2016
    Assignees: Novo Nordisk A/S, Sanquin Blood Supply Foundation
    Inventors: Henriet Meems, Alexander Benjamin Meijer, Koenraad Mertens, Ole Hvilsted Olsen, Kasper Lamberth, Peder Lisby Noerby, Laust Bruun Johnsen, Marianne Hjortnæs Kjalke, Henning Ralf Stennicke, Johannes Voorberg, Maartje Van Den Biggelaar